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Apocrine gland anal sac adenocarcinoma (AGASACA) of the dog is a frequently 
invasive and metastatic tumor and is commonly associated with peripheral hypercalcemia due to 
circulating elevated parathyroid hormone-related protein (PTHrP). As the tumor name implies, 
this neoplasm is attributed to apocrine gland origin, and special staining is not typically 
performed for additional investigation. Few studies have pursued additional characterization of 
these masses and identified evidence of neuroendocrine differentiation within some canine anal 
gland tumors. At this time, however, the significance of this finding is unknown, though 
additional examination may reveal relationships between neuroendocrine differentiation and the 
occurrence of peripheral hypercalcemia, PTHrP expression (a frequent underlying cause of 
peripheral hypercalcemia), metastasis at time of diagnosis, and/or patient survival time.  
The first objective of this study was to validate a PTHrP antibody for use in canine 
histology sections of AGASACA tumors. Secondly, we set out to determine if tumors that 
display neuroendocrine differentiation more commonly express PTHrP (a frequent underlying 
cause of peripheral hypercalcemia). A subset of canine anal sac apocrine gland tumors was 
retroactively evaluated via immunohistochemistry to determine tissue differentiation, histologic 
tumor pattern, and PTHrP expression. The third objective was to determine if a correlation 
between tumor PTHrP expression and peripheral hypercalcemia existed. The presence or absence 
of peripheral hypercalcemia was recorded by retrospective review of medical records for all 
patients within the study.  Lastly, the relationships between histologic pattern and 
neuroendocrine differentiation, PTHrP expression, and peripheral hypercalcemia were evaluated. 
Tumor patterns were recorded during microscopic evaluation and the tumors were separated into 
one of seven groups based on their specific pattern.  
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There was no significant relationship between hypercalcemia and histologic tumor 
pattern. Results did show a significant correlation between hypercalcemia and positive PTHrP 
expression compared to absence of PTHrP expression. No statistical analysis was performed 
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Neoplasms associated with the canine anal glands may arise and are known as apocrine 
gland anal sac adenocarcinoma (AGASACA) of the dog; this is a frequently invasive and 
metastatic tumor, commonly spreading to regional lymph nodes1,2,3,4,5.  As the tumor name 
implies, this neoplasm is attributed to apocrine gland origin, and special staining is not typically 
performed for additional investigation with routine histopathologic evaluation. Histologically, 
these tumors can display variable morphologic patterns and few studies have pursued additional 
characterization of these masses; however, there is evidence of neuroendocrine differentiation 
within canine anal gland tumors, a finding of uncertain clinical significance5,6,7. 
At presentation, affected patients may present with a range of clinical signs; however, in 
some instances, the neoplasm is an incidental finding on a routine rectal examination. Treatment 
options for AGASACA include surgical removal of the mass, variable radiation doses, and 
chemotherapy. Treatment is determined on a case-by-case basis, with some patients requiring 
only surgery and others benefiting from a combination of treatment modalities8. Canine 
AGASACA is locally invasive and has a high rate of metastasis1,3. Median survival time (MST) 
for this neoplasm is highly variable depending on the report and characteristics of included cases, 
but some animals have a long survival time with care.  
Hypercalcemia, due to elevated parathyroid hormone-related protein (PTHrP) circulating 
in peripheral blood, has been reported to occur in 27% to 51% of AGASACA patients and is 
considered a negative prognostic factor1,6. Calcium homeostasis is normally tightly regulated 
within the body, in large part due to the action of the parathyroid gland. Dogs with AGASACA 
and hypercalcemia have been found to have substantially elevated PTHrP concentrations, while 
2 
 
normocalcemic dogs with AGASACA had undetectable PTHrP concentrations9. Parathyroid 
hormone-related protein can alter serum calcium concentrations in several ways. Disruptions in 
the normal bone environment due to metastatic disease can also lead to alterations in calcium 
concentrations within the body. However, while metastasis of AGASACA is common, it rarely 
metastasizes to bone; rather, metastasis usually occurs first at the draining lymph nodes, later 
progressing to the liver and spleen1. 
AGASACAs are intriguing from a clinicopathologic perspective because they display 
microscopic characteristics similar to those observed in cytology preparations of tumors of 
neuroendocrine origin (ex. insulinoma). The cells within these tumors are round to cuboidal to 
columnar, small to medium in size with pale, eosinophilic, slightly granular cytoplasm, and 
commonly have indistinct cell borders. Nuclei are round and medium-sized, one to two small 
nucleoli are usually present, and the cells are commonly arranged in various patterns3,10. Despite 
the unusual cytologic appearance, histopathologically, apocrine glandular tissue is the reported 
origin for canine AGASACA. The neoplastic tissue does not present a diagnostic challenge with 
routine hematoxylin and eosin (H&E) stain, as AGASACA tumors have distinctly different 
histomorphologic features from other common tumors found in this area10,11. Interestingly, 
several studies have found evidence of neuroendocrine differentiation within AGASACAs5,6,7. 
One study described the immunohistochemical staining properties of canine AGASACA and 
found positive-staining neuroendocrine cells in limited numbers throughout the 8 tumors 
evaluated5. Neuroendocrine differentiated cells within anal gland tumor tissue may play a 
clinically important role in tumor biology and/or disease progression.  
Another study evaluated histologic growth patterns (solid, rosette, tubular, mixed) and 
neuroendocrine differentiation of AGASACA to assess for relationships to clinical outcome7. 
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Links were not identified, but case numbers in the evaluated groups were low. In review of the 
canine AGASACA literature, the author was unable to identify studies with large case numbers 
that assessed for clinical differences between tumors that display neuroendocrine differentiation 
and those that do not. In particular, it is unknown whether tumors that display neuroendocrine 


























Apocrine Gland Adenocarcinoma of the Anal Sac 
 Assorted glands are found within the skin, including sebaceous and modified sebaceous 
glands, apocrine and modified apocrine glands, and merocrine glands12. Many of these same 
glands are found around the perianal region of the dog, with the addition of the circumanal 
(hepatoid) glands and apocrine glands of the anal sac6,11,13. Canine anal sacs are two structures 
located laterally to the anus between the muscles of the sphincter ani externus and internus. They 
are composed of connective tissue, apocrine glands, sebaceous glands, and low numbers of 
neuroendocrine cells, with a lining of stratified squamous epithelium5,14. Apocrine cells are 
cohesive and glandular epithelial cells that are distributed throughout the hairy skin of most 
mammals, including the dog. Depending on their location, these cells excrete their product via 
exocytosis or apocrine secretion15,16. The anal sac apocrine glands are tubular mural glands that 
are distinct from the merocrine anal glands within this region17. In conjunction with sebaceous 
glands in this area, the apocrine glands fill the anal sacs with secretory products11. This serous to 
viscous fluid is light beige to dark brown, sometimes granular, and contains variable numbers of 
desquamated epithelial cells, local bacteria, yeast, and rarely neutrophils and mononuclear 
cells14,18,19. Anal sac and glandular function are thought to be related to social and territorial 
interactions, though a defensive mechanism, similar to that of the skunk, is also considered 
possible14.   
Tumors in the canine perineum are quite common and, given the variety of glands 
present, an assortment of tumors can be found11. These include perianal gland tumors and two 
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neoplasms that can arise from the apocrine glands of the anal sac—benign neoplasm, the anal sac 
gland adenoma, and the malignant form, apocrine gland adenocarcinoma of the anal sac10,12. 
These tumors cannot be differentiated from one another grossly and histopathology is required to 
differentiate the somewhat common AGASACA from the exceedingly rare anal sac gland 
adenoma12. AGASACA can occur unilaterally or bilaterally (up to 10% of cases), but the 
mechanisms driving bilateral AGASACA formation are unclear20. Currently, there is no single 
underlying or predisposing cause; however, recurrent anal sac impaction and infection have been 
noted in some patients20.  
A sex predilection towards intact female dogs was initially described in the literature, but 
more recent studies suggest a possible increased incidence in neutered male dogs10,12,17,21. Data 
describing breed predispositions are lacking overall, but Polton et al. found that English cocker 
spaniels, Cavalier King Charles spaniels, and springer spaniels have 7.3:1, 2.6:1, and 2.2:1 
averaged odds for developing AGASACA.  
Clinical signs of AGASACA are variable, though several studies indicate that perianal 
swelling and tenesmus are most common2,3,11. Polyuria, polydipsia, scooting, tumor bleeding, 
and hind limb weakness are also notable clinical findings associated with AGASACA1,2,3,10,11.  
Still, some patients display no clinical signs and tumor size can be relatively small (average 
9cm2) at the time of diagnosis; consequently, this aggressive neoplasm is an incidental finding in 
39-50% of cases2,20. In addition to difficult detection, metastasis to the sacral, internal iliac, and 
medial iliac lymph nodes tends to occur early in the disease process2,4,5. Many studies found 
greater than 50% of tumors (range 36-96%) had evidence of metastatic disease at the time of 
diagnosis, and diagnostic imaging appears to be relatively insensitive at perceiving 
metastasis2,3,4,12. Overall, diagnosis of AGASACA should include full hematology and serum 
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biochemical analysis, abdominal ultrasound, and computed tomography20.  Cytologic evaluation 
of enlarged lymph nodes may also prove helpful, as it is highly sensitive for identification of 
disease, but this may not be true for microscopic metastatic disease within normal-sized lymph 
nodes4.   
Cytologically, the epithelial apocrine cells of AGASACA lack distinct borders; 
additionally, acinar-like structures are commonly noted. These features can impart a 
neuroendocrine appearance on cytology, resembling aspirates of endocrine tissues such as 
thyroid C cell tumors, parathyroid tumors, insulinomas, chemodectomas, pheochromocytomas, 
and carcinoids22. This contrasts with the appearance typical of other epithelial glandular tissues, 
such as salivary tissue. By way of example, cytologic preparations of salivary epithelium contain 
a uniform secretory epithelial population of primarily cohesive, rounded or polygonal cells with 
distinct borders, eccentric, deeply basophilic nuclei, and clear, vacuolated to foamy cytoplasm23. 
Histologically, AGASACA is made up of neoplastic epithelial apocrine cells separated by 
fine connective tissue strands and arranged in distinctive patterns: solid, rosette, tubular, and 
mixed10. Capillaries and pseudo-rosette structures are abundant17. Suzuki et al. found that solid-
type and mixed-type tumors with solid components had poorer clinical outcomes than other 
histologic types. With H&E stain, the neoplastic cells of AGASACA are small to medium sized 
with pale eosinophilic, slightly granular cytoplasm and variably distinct cytoplasmic borders10.  
Nuclei are medium-sized and round with slight anisokaryosis and one or more small nucleoli10. 
Mitotic figures, stromal invasion, and metastasis are frequently seen5,10.  
Keratin-like proteins or cytokeratins are structural components of the cellular 
cytoskeleton that are characteristic of epithelial cells24. Vos et al. found positive cytokeratin 5, 7, 
8, 18, and 19 activity in anal sac glands of dogs with immunohistochemistry. AGASACA tumors 
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were also positive for cytokeratin 7, 10, and 18, with variable staining for cytokeratin 14, 15, 17, 
and 19; these findings supported the tissue of origin of AGASACA tumors.  
Treatment plans for patients diagnosed with AGASACA are created on a case-by-case 
basis but are generally based around surgical resection of the primary mass and enlarged lymph 
nodes, as studies have demonstrated that surgery seems to improve MST2,25. A study by 
Williams et al. asserts that patients have a 37% chance of surviving 2+ years and that dogs 
receiving surgery have a survival advantage, no matter what other adjunctive therapies are used. 
Some combination of radiation therapy or chemotherapy (carboplatin, melphalan, mitoxantrone, 
and cyclophosphamide) may also be included or used as a standalone treatment2,4.  
Bisphosphonates and saline hydration have been advised as treatments for hypercalcemia of 
malignancy26.  
Treatment complications vary depending on the chosen treatment modality. Infection, 
hypocalcemia, sudden death from anesthesia, fecal incontinence, wound dehiscence, perianal 
fistula, tenesmus, and complications due to radiation or chemotherapy can occur and reports of 
overall surgical complication rate range from 0-20%2,4. Negative prognostic indicators include 
masses that are ≥ 10cm2, lack of surgical intervention, presence of metastasis, and 
hypercalcemia1,2,20,26. 
 Survival times are strikingly inconsistent throughout the literature, with studies reporting 
MSTs of 6-8 months, 18 months, 20 months, 29 months, and 41 months1,2,25,27,28. This is most 
likely due to many disease factors such as tumor size, early or late tumor detection, presence of 
metastatic disease, peripheral hypercalcemia (average MST of 256 days for hypercalcemic 




Calcium and the Endocrine System 
Calcium plays a large and varied role in many body systems, from skeletal support, blood 
coagulation, muscle contraction, hormone secretion, stabilization of sodium channels and cell 
membranes, and cell growth and division29,30. Complexed hydroxyapatite represents 
approximately 99% of the body’s calcium supply. The remaining 0.9% and 0.1% are present 
intracellularly and extracellularly in other forms29,31. Total serum calcium consists of three 
fractions: roughly 50% biologically active ionized calcium, 40% protein-bound calcium, and 
10% complex calcium in the form of bicarbonate, citrate, phosphate, lactate, and oxalate31,32. 
Total calcium is generally reported in milligrams per deciliter (mg/dL) or millimoles per liter 
(mmol/L), and the range in serum total calcium values may be wide within groups of normal 
dogs32.  Ionized calcium is considered a more accurate measure of hypercalcemia because it only 
reports the active form of calcium31,32,33,34. As previously mentioned, calcium has many 
important and varied roles within the body, so it is of no surprise that even small increases in 
biologically active serum calcium concentrations above normal can have variable physiologic 
consequences and negative multisystemic impacts30,31,32,33.  
Calcium homeostasis is tightly regulated by parathyroid hormone (PTH), 1,25-
dihydroxycholecalciferol (calcitriol), and calcitonin31,33. Serum calcium levels are maintained by 
the chief cells of the parathyroid gland. These cells synthesize and secrete PTH to maintain an 
appropriate serum calcium concentration at the level of the kidney and bone34,35. PTH acts on the 
PTH1 receptor at the surface of renal tubular epithelial cells, osteoblasts (bone producing cells), 
osteoclasts (bone resorbing cells), and bone stromal cells to promote calcium resorption34,35. It 
also promotes urinary phosphorus excretion, triggers activation of calcitriol, and indirectly 
increases intestinal absorption of dietary calcium31. Upregulation of the receptor activator of 
9 
 
nuclear factor κ-B ligand (RANKL) on the surface of osteoblasts also occurs. Osteoblasts then 
secrete RANKL that binds to receptor activator of nuclear factor κ-β (RANK) on osteoclasts, and 
several pathways stimulate osteoclast differentiation, activation, and survival, bone remodeling, 
and release of calcium into circulation34,35,36. 
Vitamin D (as vitamin D2 and D3) is directly absorbed within the intestinal tract and 
transported to the liver. It is then hydroxylated to 25-hydroxycholecalciferol (calcidiol) and 
further hydroxylated to the biologically active form of vitamin D (calcitriol) in the kidney by 
renal 1α-hydroxylase (activated by PTH)31,34,35. Calcitriol is responsible for the daily fluctuations 
in serum calcium. It acts in a fashion similar to PTH, promoting bone resorption, release of 
calcium into circulation, and renal reabsorption of calcium. Unlike PTH, calcitriol also promotes 
renal and intestinal reabsorption of phosphorus31. Another player in calcium homeostasis is 
calcitonin, which is produced by the C cells of the thyroid gland in response to increased calcium 
levels. Calcitonin, like PTH and calcitriol, acts on bone; however, it acts to decrease blood 
calcium levels by interfering with osteoclast-mediated resorption and increases calciuresis31. 
Thus, disturbances in calcium levels leading to hypercalcemia can cause an array of 
alterations in the body including polyuria, polydipsia, vomiting, inappetence, weight loss, 
paresis, skeletal pain and fractures,37. In the dog, hypercalcemia is defined as a fasting serum 
total calcium or ionized calcium greater than 12mg/dL or 5.81mg/dL respectively32,37. The 
endocrine system, of which certain parts play large roles in calcium regulation, is generally 
thought to include the pituitary gland, thyroid gland, parathyroid gland, adrenal gland, pancreas, 
and a few other organs. These organs regulate various crucial functions within the body such as 
metabolism, stress, development, and reproduction38. Cells within the endocrine system secrete 
peptides, amines, or steroids into circulation to maintain homeostasis within the body39. Serum 
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calcium concentration is mainly regulated PTH, vitamin D metabolites, and calcitonin, and these 
three hormones largely act at the intestines, kidneys, and bone to exert their regulatory effects37.  
In the dog, two pairs of parathyroid glands are located in the cranial cervical area22. The 
cells are arranged in nests and cords, delineated by a thin fibrovascular stroma. A rich capillary 
network is noted throughout the parathyroid gland and the predominant cells are groups or 
clusters of chief cells often arranged in small groups around a central capillary, giving a 
“pseudofollicular” appearance40,41.  Histologically, these cells are cuboidal or polyhedral 
epithelial cells with lightly eosinophilic cytoplasm, but cytologically, cells with indistinct 
borders appear as free nuclei embedded in a background of lightly basophilic cytoplasm22,41. 
Other cells within the parathyroid gland include oxyphils, clear cells, and transitional oxyphil 
cells, with many believing these cells represent variations in the morphologic expression of chief 
cells41. With the help of transmission and electron microscopes, secretory granules are readily 
visible near the luminal border of variably active chief cells, which have well-developed 
organelles, aggregated endoplasmic reticulum, clustered ribosomes, and prominent Golgi 
apparatuses40. Secretory granules range from 100 to 300 micrometers and are more numerous in 
active chief cells than inactive chief cells40. The granules migrate to the periphery of the cell and 
fuse with the plasma membrane, extrude from the chief cell, detach, and enter circulation via 
nearby capillaries40.  
 
Neuroendocrine Cells 
It was recognized in the late 1800’s to 1930’s that polypeptide hormone-producing cells, 
at the time called “clear cells”, were widely dispersed not only within dedicated endocrine 
tissues, but also throughout a variety of nonendocrine tissues and organs, including 
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gastrointestinal tissue and skin39,42, 43, 44. This led to the concept of the endocrine system being 
more diffuse and dispersed throughout the body than previously realized, as well as the 
realization that the endocrine system could have local or systemic effects, leading to the term 
“diffuse neuroendocrine system” (DNES)22,42,43,44. These clear cells are now termed 
“neuroendocrine cells” (NECs). Neuroendocrine cells produce, contain, and store biologically 
active neuroamines and neuropeptides within membrane bound secretory granules42,43,45,46. These 
granules are released into the bloodstream to act as traditional neurotransmitters on cells at 
distant areas of the body and may also act on neighboring cells via paracrine signaling44,46,47. 
NECs share several cytochemical and ultrastructural characteristics and are also collectively 
referred to as amine precursor uptake and decarboxylase (APUD) cells17,44,45. These cells are 
apparently unrelated endocrine cells present in endocrine and nonendocrine tissues alike and are 
regularly present in all species45,46. Such cells include thyroid C cells that produce calcitonin, 
pituitary corticotrophs that produce ACTH, pituitary melanotrophs that produce melanocyte-
stimulating hormone, and pancreatic β cells and α2 cells that produce insulin and glucagon, 
respectively45.  
It should be noted that the term neuroendocrine cell does not imply embryologic 
derivation from the neuroectoderm because the origin of NECs is variable. Rather it is meant to 
reflect the shared phenotypic characteristics these cells have with endocrine and neuronal 
cells39,43,44,46.  Some do arise from the neuroectoderm, while others are epithelial and of 
endodermal origin, either dispersed throughout tissues or sometimes forming small structures 
within tissues. Other NECs are modified neurons that have no epithelial features and are 




Despite different origins, the majority of NECs are in fact epithelial, indicated by 
cytokeratin expression46, and all NECs express some or all of the following markers: neuron 
specific elonase, synaptophysin, secretogranins, and chromogranins (referred to collectively as 
“neuroendocrine markers”), as well as the enzymes involved in their peptide hormone 
synthesis47,48. Of these, two commonly used neuroendocrine markers are chromogranin A (CgA) 
and synaptophysin (SYN)49. Chromogranin A is equivalent to parathyroid secretory protein 1 
and is a commonly used marker for NECs in carcinomas arising in non-endocrine tissues7,48,50,51. 
Synaptophysin, primarily present in microvesicles, is a calcium-binding glycoprotein that is the 
most abundant integral membrane constituent of neuronal synaptic vesicles and is a common 
marker of NECs43,48,52. Synaptophysin has been demonstrated within neural-type and epithelial-
type neuroendocrine neoplasms, with co-expression of neurofilament protein and cytokeratins, 
respectively46. Synaptophysin is more broadly expressed than CgA, as certain neurons, some 
pancreatic islet cells, and cells with sparse granules are negative for CgA but positive for 
SYN43,46. Thus, these two antibodies are commonly used as a complementary pair.  
A few methods for determining neuroendocrine differentiation of cells have been 
developed, with silver impregnation techniques being one of the first and most useful. This 
technique utilizes the ability of endocrine cells to uptake and occasionally reduce silver ions; 
however, these techniques are very limited in poorly granulated NETs48. Advancement and 
growth of immunohistochemistry has revolutionized the ability to study these cell types, and as 
previously stated, multiple reliable markers of neuroendocrine differentiation are available48.   
 As with any cell type within the body, NECs can undergo neoplastic transformation and a 
neuroendocrine tumor can form. Neuroendocrine tumors are a family of neoplasms that vary 
widely in their morphologic features, biologic behaviors, and functional capabilities. In humans, 
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NETs often contain mixed cell types and produce more than one hormone48. Ectopic hormone 
production is also possible, in which a NET secretes the hormonal product of another endocrine 
site47. Neuroendocrine cells may be dispersed as single cells or small cell groups within a tumor, 
such as within squamous cell carcinomas, adenocarcinomas, bronchopulmonary tumors, and 
certain carcinoids43,53. In these situations, they are only recognized after application of special 
immunohistochemical stains, and the presence of a minority of NECs within a tumor may have 
no significant impact43. Detection of specific NET hormones is possible but is sometimes 
challenging; poorly granulated NETs store too little product for detection, and some tumors 
produce abnormal forms of hormones that do not react with detection antibodies46,48. Given these 
difficulties, it is recommended that an array of markers be used in order to increase proper 
classification of tumor cells48.   
In human literature, there is debate about the cellular components of neuroendocrine 
tumors. There are “pure forms,” which are NETs that are composed of neuroendocrine cells, and 
“mixed tumors” that are NETs admixed with non-neuroendocrine components43,53,54. Some 
authors require a tumor to have at least 20% non-neuroendocrine cells while others require an 
equal mix of neuroendocrine and non-neuroendocrine cells to be classified as a mixed tumor43. A 
study done by Sapino et al. looked at 50 NETs of the breast that were classified as such when 
≥50% of cells showed positivity for neuroendocrine markers. In addition to the neuroendocrine 
markers, the authors looked within these tumors for the co-expression of gross cystic disease 
fluid protein-15 (GCDFP-15), an apocrine cell marker used for determining mammary 
differentiation. Interestingly, they found that both pure-neuroendocrine differentiation and 
neuroendocrine-apocrine differentiation may be found within breast tumors55. In this study, CgA 
was the most useful neuroendocrine marker, and its expression was significantly correlated with 
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the pure-neuroendocrine type tumors. Positivity for CgA generally correlates with secretory 
activity, with cells containing numerous and well-developed secretory granules exhibiting 
intense IHC staining56. On the other hand, paucigranular cells exhibit weak staining or may be 
completely nonreactive43,48. 
Neuroendocrine tumors can be generally grouped into epithelial and neural subtypes; this 
paper focuses on the epithelial subtype, which is defined as an epithelial neoplasm with 
predominant neuroendocrine differentiation43,57. Epithelial-type NETs can exhibit a range of 
histologic and cytologic features. There are three main histologic patterns: solid-type, made up of 
nests of neoplastic cells and occasional ribbon structure; rosette-type, containing mainly rosettes 
and glandular structures; and tubular-type, which have variably sized lumens lined by neoplastic 
cells7,43. Cells may be round, polyhedral, cuboidal, or spindle-shaped and vary in size from small 
to large. Granular eosinophilic or amphophilic cytoplasm is commonly noted and some cells may 
be vacuolated43. Nuclei may be round to oval and are sometimes located in the basal area of the 
cell. The nuclei can range from small in size, with hyperchromatic chromatin, to intermediate or 
large with coarsely granular chromatin. Nucleoli may be prominent but are not always noted7,43. 
 
Hypercalcemia and Hypercalcemia of Malignancy  
Hypercalcemia can have transient, nonpathologic, or pathologic origins33. There are two 
main categories of pathologic hypercalcemia: parathyroid-dependent and parathyroid-
independent31. Parathyroid-dependent causes include primary hyperparathyroidism and 
secondary nutritional or renal hyperparathyroidism. Parathyroid-independent causes include 
transient hypercalcemia, humoral hypercalcemia of malignancy (cancer-associated 
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hypercalcemia), idiopathic, and certain toxic, metabolic, skeletal, and granulomatous 
etiologies31.  
Hypercalcemia can manifest clinically in many ways due to impairment of the renal, 
gastrointestinal, and nervous systems34,58. Within the kidney there is decreased responsiveness to 
antidiuretic hormone at the distal tubule, decreased renal blood flow and GFR, and calcium salt 
deposition58. Polyuria, polydipsia, vomiting, dehydration, constipation, hypertension, weakness, 
shaking, bradycardia, and cardiac arrhythmias can also be seen34,58.  
Neoplasia, leading to paraneoplastic syndrome (PNS), is the most common cause of 
pathologic hypercalcemia in the dog31. Paraneoplastic syndromes are neoplasm-associated 
alterations in bodily structure, function, or both that occur distant to the tumor58. This type of 
hypercalcemia is termed humoral hypercalcemia of malignancy (HHoM) and when present, 
generally translates to a poor prognosis for the patient26,31. Lymphoma and AGASACA are 
considered the first and second most common neoplasms associated with HHoM3,33,37,58,59. Ten 
to forty percent of dogs with lymphoma show signs of hypercalcemia60,61. The numbers of 
hypercalcemic patients with AGASACA vary widely but fractions around 25% are reliably 
found throughout the literature1,2,58. Other neoplasms like multiple myeloma, thyroid carcinoma, 
bone tumors, thymoma, squamous cell carcinoma, and other carcinomas also, but less 
commonly, show a relationship with HHoM34.  
Neoplasms may cause hypercalcemia via production of PTHrP (see below), ectopic 
production of PTH, extensive lytic bone metastases, primary hyperparathyroidism, tumor-
associated prostaglandin release, and other mechanisms58,61,62,63. Parathyroid hormone-related 
protein is a 160kDa protein synthesized broadly by many fetal and adult tissues and has been 
implicated as the cause of hypercalcemia in both lymphoma and AGASACA31,58,64. Parathyroid 
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hormone-related protein is structurally similar to PTH, which regulates serum calcium 
concentration, in that 8 of the first 13 amino acids are homologous to PTH. The next 21 amino 
acids, while not homologous to PTH, have been shown to effectively bind the PTH receptor, as 
the majority of differences in this region are conservative substitutions29,34,65. These structural 
similarities between PTH and PTHrP at the N-terminus of the protein are important because this 
is the functional portion of the molecule that effectively binds the PTH receptor66. In a study on 
PTHrP in human tumors, a rabbit polyclonal antiserum against PTHrP did not cross-react with 
PTH, indicating that the two peptides have distinct differences. However, PTHrP’s ability to bind 
the PTH receptor suggests that the hypercalcemia seen in PTHrP-associated hypercalcemia of 
malignancy, such as in AGASACA, is due to the ability of PTHrP to function like PTH58,67. It 
has been shown that there are structural and antigenic similarities between human PTHrP and 
canine PTHrP and according to the National Center of Biotechnology Information (NCBI), 
human and canine PTHrP are 91.53% identical68 (Figure 1).  
Parathyroid hormone-related protein expressing cells have been identified within a 
variety of normal human and canine tissues29,58,67. Some of these tissues include keratinocytes 
within the basal layer of skin, epithelium of hair follicles, apocrine glands of the skin and anal 
sac, myoepithelial cells of the anal sac, thyroid gland C cells, mammary glands, bone, smooth 
and skeletal muscles, cardiac muscle, brain, and kidney29,31,64,69. The physiologic actions of 
PTHrP within these tissues are not completely known. Some proposed actions include regulation 
of the hair cycle and hair growth, regulation of keratinocyte proliferation and differentiation, 
stimulation and inhibition at the bone, stimulation of insulin secretion and somatic growth within 
pancreatic islet cells, mammary gland development, lactation, and release by smooth muscles in 
response to stretching26,29,70.   
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The mechanism of humoral hypercalcemia of malignancy is variable across patients and 
tumors. Previous reports thought ectopic production of PTH by tumor cells was the main factor 
in generating HHoM; however, it is now believed that PTHrP is the primary factor, though the 
mechanism of increased PTHrP from neoplastic cells is not fully understood34,64,67. Local 
osteolysis is also considered an important mechanism in hypercalcemia of malignancy but less 
frequently results in hypercalcemia34. This occurs when there is a primary bone tumor or 
metastasis of a tumor to bone, which in turn activates osteoclasts to resorb bone34. For 
lymphoma, hypercalcemia in dogs may be due to HHoM or local resorption of bone due to bone 
metastasis, and studies have shown that neoplastic lymphocytes may generate hypercalcemia 
from mechanisms other than PTHrP production9,63. Kubota et al. showed that lymphoma cells 
from patients with and without hypercalcemia express PTHrP mRNA and thus can yield 
increases in circulating PTHrP. However, only patients with hypercalcemia had evidence of 
increased plasma PTHrP concentrations64. A study by Shallis et al. showed that the route of 
hypercalcemia differed between subtypes of lymphoma, and a broadly dominant mechanism as 
to the primary cause of lymphoma-associated hypercalcemia was not established. 
 
AGASACA and Humoral Hypercalcemia of Malignancy 
Parathyroid hormone-related protein is believed the primary mediator in humoral 
hypercalcemia of malignancy for AGASACA, as metastasis to bone is rare, and PTHrP has been 
detected within normal anal sac apocrine glands and AGASACA9,34,67.  The physiologic 
significance of PTHrP in the normal anal sac apocrine gland cells is unknown, and the amount of 
PTHrP produced in health may not have a significant physiologic effect on the body, instead 
only working in a paracrine fashion when disease is not present67. There appears to be correlation 
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between immunohistochemical staining for PTHrP, serum calcium concentration, and serum 
PTHrP concentration in mouse models of AGASACA62.  
A direct link between tumor production of PTHrP has been shown in a mouse model 
using two tumor variants of a canine AGASACA. Grone et al. looked at two variants of a canine 
AGASACA in a mouse model and found that PTHrP production from the tumor was positively 
correlated with serum calcium concentration. One tumor variant was a well-demarcated and 
multilobulated AGASACA that had polygonal to cuboidal neoplastic cells arranged in acini, 
tubules, cords, and sheets. This tumor showed strong IHC staining for cytokeratin, produced high 
levels of PTHrP, and marked hypercalcemia was noted in mice with this tumor. The other 
AGASACA variant was a solid tumor made up of polygonal to spindle-shaped neoplastic cells 
arranged in sheets and cords supported by connective tissue stroma. Acini were rarely observed, 
PTHrP production was low, and mild increases in calcium were noted in comparison to control 
mice62. Possibly more significant is that Suzuki et al. showed that mixed-type tumors were more 
commonly associated with hypercalcemia, suggesting that the PTHrP expression of an 
AGASACA tumor may relate to the histologic pattern. Conversely, other studies indicate that 
production of PTHrP by a tumor does not necessarily lead to hypercalcemia69. 
 Despite a correlation with hypercalcemia, not all patients with AGASACA become 
hypercalcemic. A study in humans identified PTHrP expression in 100% (34 samples) of 
squamous cell cancers but no patients were hypercalcemic67. This suggests that hypercalcemia 
occurs at a certain threshold of PTHrP production, which causes normal homeostatic control 
mechanisms to be lost; therefore, PTHrP expression by neoplastic cells should be correlated with 
serum calcium and PTHrP concentrations67,68.  
19 
 
Tumor differentiation may also be a factor in the amount of PTHrP that is produced. 
Poorly differentiated tumors may be non-functional and secrete no or low amounts of hormone, 
such that no biologic activity occurs, while more differentiated tumors may have more functional 
capacity and cause an increase in PTHrP leading to systemic effects. Dogs with poorly 
differentiated tumors may survive longer and have a better prognosis than dogs with more 
differentiated tumors (i.e. have hypercalcemia)2.   
 
Anomalous AGASACA IHC Activity 
It is previously established that the neoplastic cells that make up AGASACA are 
epithelial in origin. Interestingly, a few studies have determined that some normal anal sac 
apocrine gland cells, as well as neoplastic AGASACA cells, are positive for multiple 
neuroendocrine markers (chromogranin A and neuron-specific enolase)5,6,7. Synaptophysin has 
also been identified within AGASACAs but has not been noted within non-neoplastic apocrine 
cells6. Some non-NETs have also shown elevated CgA and neuroendocrine differentiation, 
which sometimes correlated with progression and poor prognosis71. There are rare reports of 
malignant apocrine carcinomas with neuroendocrine differentiation in human literature. Li et al.  
reported a tumor composed of cells that were round to polygonal with eosinophilic cytoplasm 
and a second population with abundant pale to foamy cytoplasm. Both cell types had enlarged 
nuclei with distinct nucleoli and were arranged in either a micronodular pattern or solid nests 
surrounded by densely fibroblastic stroma. Glandular or rosette-like structures (ductal lumina) 
were identified within the tumor. Immunohistochemistry revealed that tumor cells were positive 
for pan-cytokeratin, CK7, epithelial membrane antigen, and more than 80% were positive for 
synaptophysin and CgA72. If canine AGASACAs are found to consistently have significant 
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numbers of neuroendocrine positive cells, it may suggest a link to cancer-associated 

























MATERIALS AND METHODS 
 
Hypothesis  
1. PTHrP expression is affected by tumor pattern of canine AGASACA 
2. Tumors with greater neuroendocrine differentiation will express higher levels of PTHrP 




1. Validate PTHrP antibody for use in canine tissue samples 
2. Evaluate the association between neuroendocrine differentiation and PTHrP antibody 
expression within canine AGASACA  
3. Assess the relationship between peripheral calcium levels and PTHrP antibody 
expression within canine AGASACA 
4. Assess the relationship between histologic tumor pattern and neuroendocrine 
differentiation in canine AGASACA 
5. Assess the relationship between histologic tumor pattern and PTHrP antibody staining 
within canine AGASACA 







Study cases were selected from among archived tissues of canine anal gland tumors 
previously submitted to the Veterinary Diagnostic Laboratory (VDL) at the University of Illinois 
at Urbana-Champaign for histological diagnosis. The laboratory information system was 
searched for canine patient records between July 2008 and August 2019 in which the diagnosis 
of AGASACA was made histologically. Search terms included “AGASACA”, “apocrine gland 
anal sac adenocarcinoma”, “anal gland adenocarcinoma”, and “anal sac adenocarcinoma”. 
Clinical information was retrospectively obtained from medical records and the inclusion criteria 
consisted of a biochemical or ionized calcium measurement prior to surgical excision or 
euthanasia, confirmation of the previous histologic diagnosis of AGASACA, and sufficient 
archived tumor tissue (preserved, paraffin-embedded) to be further sectioned, stained, and 
evaluated. Archived H&E stained sections of the original tumors were briefly reviewed (SC, PR) 
to confirm agreement with the original tumor diagnosis. One hundred and forty-three cases were 
identified that fit the inclusion criteria. To ensure a representative group of tumor cases while 
balancing project costs, 120 of the 143 cases were included in this study. The decision to include 
120 cases was based on recommendations from the American Society of Veterinary Clinical 
Pathologists for determination of de novo reference intervals73. 
 
Tissue Fixation, Processing, and Routine Staining 
At the time of original submission, the tissue samples were fixed in 10% neutral buffered 
formalin. The tissues were processed routinely, embedded in paraffin wax and 5 µm sections 
were fixed onto slides. Slides were stained with H&E (process details below) using an automated 
stainer (Sakura) and a coverslip was applied. 
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1. Three changes of xylene at 3 minutes each 
2. Two changes of 100% alcohol at 1 minute each 
3. One minute in 95% alcohol  
4. One minute in 70% alcohol  
5. Rinse with deionized (DI) water for two minutes 
6. Hematoxylin applied for 3 minutes and followed by a water rinse 
7. Define – 30 seconds followed by water rinse 
8. Blue Buffer applied for 1 minute and followed by a water rinse 
9. One minute in 80% alcohol 
10. Eosin applied for 1 minute 
11. One minute in 95% alcohol 
12. Three changes of 100% alcohol at 1 minute each  
13. Three changes of xylene at 1 minute each 
 
PTHrP Antibody Validation  
 Canine haired skin samples were used to validate the PTHrP antibody67,69,74. The 
antibody was optimized to identify the best performance. Dilutions and incubation times tested 
are as follows: 1:50 for 1 hour, 1:100 for 30 minutes, 1:100 for 1 hour, 1:100 for 2 hours, and 
1:200 for 30 minutes. Each dilution was evaluated by SC and AS at low and high-power 
objectives. The 1:100 dilution for 2 hours was determined to give the best stain uptake with least 
background interference and was elected for use in the study.  
IHC procedure for PTHrP antibody was as follows: 
1. Antigen retrieval 
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i. Tissues were deparaffinized for at least 2 minutes in three changes of 
xylene, two changes of 100% ethanol, two changes of 95% ethanol, and a 
70% ethanol solution 
ii. Pretreatment with Diva Decloaker at 125℃ for 30 seconds at 15-20 PSI 
and then 85℃ for 10 seconds. Half the solution was decanted and refilled 
with tap water. This was repeated three times. The sample was then rinsed 
with tap water and two changes of TBS auto wash buffer.  
2. Peroxidazed 1 was applied for 5 minutes 
3. Blocked with background punisher for 10 minutes 
4. Application with 1:100 dilution of PTHrP antibody for 2 hours 
5. Secondary antibody was applied for 30 minutes, washed with buffer, and the 
secondary antibody was again applied for 30 minutes 
6. 3,3′-Diaminobenzidine (DAB) was applied for 5 minutes 
7. Counter-stained with cat hematoxylin for 5 minutes 
8. Washed with buffer and deionized water  
 
Immunohistochemistry Methods 
Cytokeratin (epithelial marker), CgA (neuroendocrine marker), and SYN 
(neuroendocrine marker) were used to classify tumor cell lineage.  IHC was performed using 
cytokeratin (CYK; Biocare Medical, pan-cytokeratin for CK8 and CK18; prediluted mouse 
monoclonal antibody), chromogranin A (ImmunoStar, rabbit polyclonal antibody diluted to 
1:2000), synaptophysin (Biocare Medical, mouse monoclonal antibody, 1:100), and PTHrP 
antibody (ABCAM74, rabbit polyclonal antibody, 1:100). Standard VDL control tissues were 
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used for each stain; sections of canine skin were used as positive controls for CYK, canine 
pancreas and adrenal tissue were used as positive controls for CgA, and canine pancreas and 
adrenal tissue were used as positive controls for SYN6,7. Sections of canine skin were used as 
positive controls for the PTHrP antibody67,69.  The same tissues were used as negative controls, 
in which the primary antibody was omitted, and a universal polymer negative serum was placed 
on the slide. 
 IHC procedure for all samples was as follows: 
1. Antigen retrieval 
2. Peroxidazed 1 was applied for 5 minutes 
3. Blocked with Background Punisher for 10 minutes 
4. Application of primary antibody 
a. CYK, CgA, and SYN: 30 minutes 
b. PTHrP: 2 hours 
5. Secondary antibody applied for 30 minutes, washed with buffer, and then applied 
again for 30 minutes 
6. 3,3′-Diaminobenzidine (DAB) was applied for 5 minutes 
7. Counter-stained with cat hematoxylin for 5 minutes 
8. Washed with buffer and deionized water  
 
Tumor Pattern 
 Histology sections (H&E and CYK) were evaluated at 12.5x, 20x, 100x, 200x, and rarely 
400x and 500x (oil) magnification to clarify details regarding morphologic patterns. Tumors 
were classified as solid, rosette, tubular, and mixed (see below). Classification guidelines were 
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based on established histomorphologic descriptions of this tumor and from a study by Suzuki et 
al.3,10,11,12 Solid tumors had sheets of round, normochromatic cells with a round, hyperchromatic 
nucleus, a prominent nucleolus, and a small amount of lightly eosinophilic cytoplasm. These 
cells were arranged in solid groups and nests surrounded by thin fibrovascular stroma and many 
solid tumors had small acinar structures formed around a central capillary or venule throughout. 
Rosette tumors consisted of cuboidal to columnar-shaped cells with a small to moderate amount 
of apical, lightly eosinophilic, cytoplasm and basilar-located rounded nuclei. Cells were arranged 
radially around variably sized circular lumen; these arrangements were commonly observed in 
groups and made up the majority of the tumor. Tubular tumors had large and variably sized 
lumina lined by rounded to cuboidal cells with a small amount of cytoplasm and round, 
hyperchromatic nuclei. Mixed tumors had clear and substantial evidence of 2 or more distinct 
patterns and were categorized accordingly (Solid + Rosette, SR; Solid + Tubular, ST; Rosette + 
Tubular, RT; and Solid + Rosette + Tubular, SRT).  
 
Categorization of IHC Markers  
IHC sections were microscopically evaluated at 12.5x, 20x, 100x, 200x, and rarely 400x, 
500x (oil), and 1000x (oil) magnification. Higher magnifications were used to determine fine 
details and intracellular staining patterns. CYK expression was graded as positive or negative; 
positive samples were those in which greater than 50% of the cells displayed cytoplasmic 
cytokeratin reactivity. Cytoplasmic reactivity was defined as diffuse brown and slightly granular 
staining throughout the cytoplasm of cells.   
Expression of neuroendocrine markers (CgA and SYN) and PTHrP were graded as 
negative (<5% of cells staining positive), weak (5-20% positive cells), moderate (21-50% 
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positive cells), and strong (>50% positive cells) based on subjective assessment by SC and PR at 
the previously mentioned microscopic magnifications. These grading percentages were based on 
a previous study by Suzuki et al. Evaluation of CgA and SYN rarely required magnification 
higher than 200x. PTHrP evaluation rarely required the use of greater than 500x (oil).  
Estimated percentages of reactive cells for CgA, SYN, and PTHrP were determined at 
12.5x, 40x, 100x, and 200x magnification. Tumor sections were divided into parts (1 part is 
equal to 1 microscopic field) depending on the size of the tumor. In each field the number of 
positive tumor cells were subjectively estimated. The estimated percentages of each field were 
added together and averaged by the number of fields counted (i.e. if twelve 200x fields were 
counted, these estimated percentages would be added together and divided by 12 to obtain the 
average estimated percentage of positive cells for the tumor). The number obtained was then 
used to categorize the tumor. If the estimated percent of positive cells was on a categorical cutoff 
(i.e. 4 or 5%; 20 or 21%; 50 or 51%) the process was repeated twice more on the tumor section 
and the three estimated percentages were added together, divided by three, and the resulting 
percent was used to categorize the tumor.  
 
Statistical Analysis  
Contingency tables were constructed using the data collected, including pattern types, 
presence of hypercalcemia, and PTHrP antibody expression. Depending on sample size for each 
category, data was analyzed using the Fisher’s exact test and Pearson’s chi-squared test to 
determine the relationship of hypercalcemia to histomorphologic tumor pattern or PTHrP 
antibody expression. A two-tailed t-test assuming unequal variances was performed to determine 
if age differed between male and female patients. A two-tailed t-test assuming equal variances 
28 
 
was performed to determine if age differed between normocalcemic and hypercalcemic patients. 
One way analysis of variance (ANOVA) was performed to evaluate the relationship between 
calcium values (mg/dL) and PTHrP antibody expression. Ionized calcium values in mmol/L were 
not analyzed as too few cases were available to determine significance within the study 
population. A p<0.05 was used to determine statistical significance. All data was analyzed in 























Sex and Age Predilection 
Males and females made up 67.5% (81/120) and 32.5% (39/120) of the cases, 
respectively, with 98.3% (118/120) being neutered or spayed. A t-test assuming unequal 
variances failed to show a significant difference in the mean age of male and female patients 
diagnosed with AGASACA (p=0.84). A t-test assuming equal variances showed no significant 
difference in age of hypercalcemic and non-hypercalcemic patients (p=0.82). 
The average age for the entire study population was 10.5 years, with a range of 5.4 to 
18.5 years. The selected cases included 80 castrated males, 38 spayed females, 1 intact female, 
and 1 intact male. The age range for males was 5.4 years to 18.5 years with an average age of 
10.5 years. The age range for females was 5.7 years to 14 years, with an average female age of 
10.4 years. Breeds included 38 mixed breed dogs, 8 each of German shepherds and Labrador 
retrievers; 6 American cocker spaniels; 5 golden retrievers; 4 miniature schnauzers; 3 each of 
Australian shepherds, boxer dogs, cockapoos, collies, and miniature dachshunds; 2 each of 
American Staffordshire terriers, beagles, bichon frises, Cavalier King Charles spaniels, German 
shorthaired pointers, goldendoodles, Irish terriers, labradoodles, Rhodesian ridgebacks, and spitz; 
and one of each of the following: Airedale terrier, Alaskan husky, Australian cattle dog, basset 
hound, border collie, Brittany spaniel, Chesapeake Bay retriever, dachshund, English cocker 
spaniel, English springer spaniel, Irish setter, Norwegian elkhound, Portuguese water dog, 




Histopathology, Tumor Patterns, and Hypercalcemia 
The AGASACAs were categorized as solid (52/120; Figure 2), rosette (5/120; Figure 3), 
tubular (4/120; Figure 4), and mixed (59/120) tumors. Mixed tumors were further divided into 
specific subgroups of solid + rosette (SR; 24/120), solid + tubular (ST; 11/120), rosette + tubular 
(RT; 12/120), and solid + rosette + tubular (SRT; 12/120) (Table 1). Fisher’s exact probability 
test and Pearson’s chi-squared test showed no dependence of hypercalcemia on any of the seven 
histologic tumor patterns. There was also no significant dependence of hypercalcemia on the 
number of patterns present in one tumor (i.e. non-mixed tumors vs. mixed tumors; 1 pattern, 
p=0.916; 2 patterns, p=0.746; 3 patterns, p=0.492).  
 
Immunohistochemistry 
All 120 tumors were overwhelmingly positive for cytokeratin (>50% of the cells were 
positive) (Figure 5). There was mild to moderate background interference with chromogranin A 
(Figure 6), and most slides had a mild, light brown-orange hue. Interference staining was usually 
worse around the periphery of the tissue sections (Figure 7). When positive staining was 
observed, it appeared as fine, tan-brown granules in small aggregates, usually near the nucleus, 
and rarely diffusely spread throughout the cytoplasm. Rarely, tumors approached the 5% cutoff 
for CgA activity, but the overwhelming majority of samples showed far less than 5% CgA 
reactivity and all tumors were graded as negative. When present, non-neoplastic, normal-
appearing glandular tissue occasionally showed positive reactivity for CgA (Figure 8). These 
cells were typically found in areas not affected by neoplastic cells, made up an exceedingly small 
portion of cells within the sample, and were not included when determining CgA reactivity for a 
given tumor.  
31 
 
All 120 tumors were graded as negative for synaptophysin. Positive SYN reactivity, 
noted as very fine, granular, diffuse, light brown, cytoplasmic staining, was exceedingly rare 
within samples. The vast majority of tumors showed nearly 0% reactivity for SYN (Figure 9). A 
single tumor showed positive SYN activity in approximately 3% of the neoplastic cells, in a 
focal area (Figure 10). No positive SYN activity was noted in non-neoplastic, normal-appearing 
anal sac apocrine glands.  
As no tumors within the study population were categorized as positive for either 
chromogranin A or synaptophysin, no statistical testing was performed regarding neuroendocrine 
differentiation. The results for CgA and SYN activity are summarized in Table 1.  
 
PTHrP and Hypercalcemia   
Tumors were grouped by their subjective expression of PTHrP antibody. Of the 120 
tumors, 62 (51.6%) were negative for PTHrP, 25 (20.8%) were weakly positive for PTHrP, nine 
(7.5%) were moderately positive for PTHrP, and 24 (20%) were strongly positive for PTHrP 
antibody expression (Figure 11; Table 1). When all tumors with positive PTHrP expression 
(weak + moderate + strong) were grouped together, Pearson’s chi-squared test showed 
significant correlation between positive PTHrP expression and peripheral hypercalcemia (p < 
0.05, p=0.02). Occasionally, PTHrP positive material was observed within acinar structures 
(Figure 12). This reactivity was not counted towards PTHrP categorization, as this staining was 
not cytoplasmic.    
Thirty cases exhibited evidence of hypercalcemia (Table 1). The PTHrP expression 
within these tumors was: 10 (33.3%) negative, 8 (26.6%) weakly positive, 2 (6.6%) moderately 
positive, and 10 (33.3%) strongly positive for PTHrP antibody. One way analysis of variance 
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showed no significant correlation between peripheral calcium concentrations (mg/dL) and 
PTHrP activity.  
 
Bilateral and Recurring AGASACA 
In thirteen instances, bilateral AGASACA samples were submitted from a single patient, 
and these tumors were evaluated as separate tumors (26 total tumors; Table 2). Of these 13 cases, 
three had the same pattern and same PTHrP expression, one had the same pattern and different 
PTHrP expression, five had the same PTHrP expression but different patterns, and four had 
different patterns and different PTHrP expression. 
There were three instances in which a dog had same site recurrence of previously excised 
AGASACA (Table 3). Case one had recurrence at 14 months. A change in histologic pattern was 
noted and PTHrP expression stayed the same; this patient was not hypercalcemic. Case two had 
recurrence at 19 months. A change in histologic pattern and PTHrP expression were noted; this 
patient was not hypercalcemic. Case three had recurrence at 14 months. Histomorphologic 
pattern was maintained in this patient, a change in PTHrP expression was noted, and 














Multidirectional differentiation, in which neuroendocrine tumors have evidence of non-
neuroendocrine differentiation and non-neuroendocrine tumors contain subpopulations of 
neuroendocrine cells, has been shown to occur in humans53. Other studies have described 
neuroendocrine differentiation within AGASACA neoplasms, and it is a somewhat strange 
finding that, not only were all tissue sections negative for both neuroendocrine markers in this 
study, but that reactivity very rarely reached even 1% for either marker7.  
Problems with the chromogranin A marker were apparent from the beginning of this study. A 
variable but extensive degree of background interference was present within CgA tissue sections 
and because of this, extra time was taken to appropriately classify and evaluate these samples. 
Background interference was also observed in positive control samples but not negative controls. 
Multiple issues can arise that may lead to background staining, such as the presence of 
endogenous enzymes, endogenous biotin or lectins, secondary antibody cross-reactivity, and 
nonspecific antibody binding. However, Burchwalow et al. states that endogenous enzymes, 
endogenous biotin or lectin, and non-specific antibody binding are not really problems in the 
world of IHC today. 
The background staining increased the threshold at which neoplastic cells were deemed truly 
positive. As a result, this decreased the sensitivity of the CgA marker and truly positive cases 
may have been missed. While this possibility should be seriously considered, it seems 
improbable that background interference caused significant alterations in the findings concerning 
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neuroendocrine differentiation, as all tissue sections were also steadily negative for 
synaptophysin immunostaining (a broader neuroendocrine marker)46. Studies that have found 
evidence of CgA positive cells within AGASACA neoplasms do indicate that the staining of 
neoplastic cells was variable, sometimes low in intensity, and CgA expression was located 
around the periphery of neoplastic cell nests6,7. While these studies demonstrate more convincing 
evidence of cytoplasmic staining for neuroendocrine markers, given the findings of this study, it 
should be considered that background interference may have played a role in the 
overinterpretation of neuroendocrine expression. Similar CgA and SYN antibodies, rabbit 
polyclonal and mouse monoclonal respectively, used in other studies were used in this study6,7. 
Higher concentrations of the antibodies for both CgA (1:2000) and SYN (1:100) were used in 
this study when compared to other studies, which used a 1:3000 dilution for CgA and a 1:500 
dilution for SYN6,7. It is unclear, but considered unlikely, that the differences in antibody 
dilutions would have significantly impacted the results of this study, as positive control tissues 
displayed expression of the neuroendocrine markers. Furthermore, the author deems the minor 
differences in tissue processing between this study and other studies unlikely to have contributed 
to differences seen in neuroendocrine expression6,7. 
The significance of the single case with roughly 3% SYN positive cells is unknown. The 
staining of these cells was not correlated with CgA or PTHrP activity, as these cells and the 
neoplasm as a whole were negative for both. Due to cost, staining with a third available 
neuroendocrine marker, neuron specific enolase, was not pursued. Additionally, this marker 
lacks specificity and its expression within AGASACA tumors is variable in other studies5,7,76.  
The cytoplasmic granularity of the neoplastic cells is another consideration for the lack of 
neuroendocrine staining that was observed. Low granularity cells have been shown to be 
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negative for CgA48. In our study, it seems unlikely that all 120 AGASACA tumors would have a 
similar low granularity cellular morphology that hindered identification of neuroendocrine 
differentiation. Neuroendocrine cells use complex cellular pathways to store protein hormones 
within secretory granules77. Alterations in cell signaling, protein folding, and protein sorting 
within the neoplastic cells could have led to no or low CgA and SYN activity being noted. 
Classification systems in human medicine usually recognize two major groups of neuroendocrine 
carcinomas—well-differentiated and poorly-differentiated neuroendocrine carcinomas. Well-
differentiated NETs express keratins and specific markers for neuroendocrine differentiation, 
such as CgA and SYN, but sensitivity and specificity of IHC markers can be reduced for poorly 
differentiated NETs78. A similar mechanism cannot be entirely excluded in the current study. 
When looking at the totality of evidence in this study, the author concludes that these cells 
are not consistent with cells displaying neuroendocrine differentiation, as they showcased no 
neuroendocrine marker activity. Use of GCDFP-15, a marker of apocrine tissue, may have 
benefitted this study in terms of complete classification of the neoplastic cells55. Even though 
almost no neuroendocrine activity was noted within neoplastic cells, complete classification of 
these cells as apocrine origin would have been valuable.  
 
PTHrP Expression  
It is known that neoplastic cells can, but do not always, produce and secrete the same 
hormones of the cells from which they derive79,80. Positive PTHrP staining was found in 58 of 
the 120 neoplasms evaluated, but hypercalcemia was not noted in all these cases. This begs the 
question—how can both positive and negative PTHrP tumors cause hypercalcemia? A fully 
accurate and comprehensive answer to this question is difficult due to the myriad of factors at 
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play. Neoplasms leading to hypercalcemia may produce an abnormal variant of PTHrP that is 
undetectable with available antibodies. If the structure of the hormone was altered within the 
neoplastic cells, the polyclonal rabbit PTHrP antibody may not have been able to highlight 
PTHrP in some cases within this study. It is also possible that PTHrP is undetectable within 
neoplastic cells due to release and secretion of PTHrP at faster rates than it is synthesized or 
stored78. Lastly, other factors, such as interleukin-1, prostaglandins, and transforming growth 
factors, may have important roles in calcium regulation in patients with AGASACA but these 
factors were not evaluated in this study79,81,82. 
 
Tumor Patterns 
 As previously stated, no relationship was observed between hypercalcemia and tumor 
pattern. However, the small sample size for some of the tumor pattern groups could be 
considered as a limitation of this study. Five cases of the rosette pattern and four cases of the 
tubular pattern were observed. These small sample sizes decrease the power of statistical analysis 
and a larger sample size may have altered the results. This same issue arose with the analysis of 
PTHrP expression and tumor pattern, where too few cases were available for meaningful 
analysis. 
 
Calcium Measurements  
Not all hypercalcemic patients had tumors that were positive for PTHrP expression. PTHrP 
expression within AGASACA tumors correlated with hypercalcemia in this study, but this 
finding calls into question whether PTHrP is the only or even primary factor that contributes to 
hypercalcemia in the AGASACA patient. The retrospective nature of this study did not allow for 
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measurement of serum PTHrP, which would have been valuable in the assessment of PTHrP and 
may have been a better assessment of PTHrP expression. Correlating this study’s findings to 
circulating concentrations of PTHrP may help build a stronger a link between calcium regulation 
and tumor PTHrP expression.  
A limitation of this study was the inability to recover serum ionized calcium (iCa) 
measurements in all patients. Serum iCa evaluates the biologically active portion of calcium in 
the body, and total calcium is not able to accurately predict iCa83. This would be a useful 
addition to a prospective study design. 
 
Bilateral and Recurring AGASACA 
Too few cases of recurrent (n =3) and bilateral (n=13) AGASACA were present in this study 
to draw meaningful conclusions. However, it was interesting to note that time between surgical 
removal in the three recurrent cases of AGASACA was 14-19 months, with 15.7 months being 
the average. Other studies have reported recurrence times of 6-10 months1,84. Continued 
monitoring of patients after surgery can aid in earlier detection of recurrence and possibly longer 
survival times.   
Currently, it is unclear whether metastasis of a primary AGASACA leads to bilateral disease 
or if two independent tumors arise within the anal sacs20. Cases have been documented where 
AGASACA appears within a previously “normal” anal sac after complete resection of 
AGASACA of the other anal gland20. It would be possible for a patient to present with unilateral 
AGASACA and have undetectable disease within the other anal sac. Further investigation, such 
as bilateral anal sacculectomy in dogs with unilateral disease, may be useful in additional 
characterization of this neoplasm. In this study, four bilateral AGASACA cases had tumors with 
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the same histologic pattern. Eight bilateral tumors had the same PTHrP activity, and three had 
the same histologic pattern and PTHrP activity. Differing histologic patterns in these samples 
may indicate these tumors formed separately from one another. However, many cellular changes 
occur during neoplastic transformation, which could lead to different phenotypes arising from 
the same neoplastic population of cells. Epithelial field carcinogenesis is a proposed explanation 
for the development of multiple primary or locally recurrent tumors, due to the presence of 
histologically and genetically abnormal tissue surrounding the original neoplasm20. This would 
be a fitting explanation for AGASACA if a concrete correlation between AGASACA 





















The following can be concluded from the present study: 
• Rabbit polyclonal PTHrP antibody is validated for use in canine skin and AGASACA to 
monitor cellular PTHrP activity. 
• There is a significant correlation between PTHrP and hypercalcemia when ≥5% of 
apocrine gland anal sac adenocarcinoma cells express PTHrP activity.  
• Apocrine gland anal sac adenocarcinoma is an epithelial tumor without neuroendocrine 
differentiation (chromogranin A and synaptophysin). 
• The mean age of male and female dogs that develop AGASACA is roughly 10 years. 
 
Future directions of this work may include detailed pursuit of the basic mechanism and role of 
PTHrP within the canine anal sac, as well as an intensive look into how malignant transformation 
alters the production and bioactivity of PTHrP. Overall, continued evaluation of tissue 
differentiation, PTHrP expression, and their roles in humoral hypercalcemia of malignancy may 
lead to earlier detection of disease, advancements in therapeutics used to treat dogs with 









FIGURES AND TABLES 
Figure 1.  
Comparison of human PTHrP (top) and canine PTHrP amino acids 
1    MQRRLVQQWS VAVFLLSYAV PSCGRSVEGL SRRLKRAVSE HQLLHDKGKS IQDLRRRFFL  60 
1    MLRRLVQQWG VAVFLLSYSV PSCGRSVEEL GRRLKRAVSE HQLLHDKGKS IQDLRRRFFL  60 
 
 
61   HHLIAEIHTA EIRATSEVSP NSKPSPNTKN HPVRFGSDDE GRYLTQETNKV ETYKEQPLK  120 
61   HHLIAEIHTA EIRATSEVSP NSKPAPNTKN HPVRFGSDDE GRYLTQETNKV ETYKEQPLK  120 
 
121  TPGKKKKGKP GKRKEQEKKK RRTRSAWLDS GVTGSGLEGD HLSDTSTTSL ELDSRRH  177 
121  TPGKKKKGKP GKRKEQEKKK RRTRSAWLNS GVAESGLEGD HPYDISATSL ELNLRRH  177 
 






Homo sapien PTHrP: https://www.ncbi.nlm.nih.gov/protein/NP_945316.1 

















































































































































































































Figure 6. Pancreas (top): Positive CgA cells display moderately to deeply brown, cytoplasmic staining, 
with the most intense positivity in small aggregates near the nucleus. Light brown interference is noted 
within negative CgA cells. IHC. x500. AGASACA (bottom): Light brown interference is present 














































Figure 7. Top: An example of an AGASACA with worsening interference for CgA at the 
peripheral edge of the sample. IHC. x100. Bottom: Light brown, indistinct staining for CgA at 
the peripheral edge of an AGASACA tissue section. Rare cells contain positive CgA granules 














































Figure 8. An area of non-neoplastic, apocrine gland cells. Low numbers of these cells are truly 















































Figure 9.  Top: SYN positive cells within the adrenal medulla. IHC. x100. Bottom: AGASACA 















































Figure 10. Small, focal area within a single AGASACA that contained SYN positive cells. A light 
brown, granular, cytoplasmic stain is observed. Overall, less than 5% of the neoplastic cells within this 














































Figure 11. Top: Tubular pattern AGASACA with moderate PTHrP activity. Many cells in this 
image display variably brown cytoplasmic staining. PTHrP antibody. x500.  Bottom: Mixed 
pattern AGASACA with weak PTHrP activity. Few cells display granular, golden brown, 















































Figure 12. Two separate AGASACA tumors with moderate (top) and strong (bottom) PTHrP 











Table 2.  














































  Histologic pattern PTHrP activity  
Tumor 1.1 Solid Negative 
Tumor 1.2 Mixed; S + R Negative 
        
Tumor 2.1 Mixed; S + T Negative 
Tumor 2.2 Solid Negative 
        
Tumor 3.1 Mixed; S + R Negative 
Tumor 3.2 Solid Negative 
        
Tumor 4.1 Solid Negative 
Tumor 4.2 Mixed; S + R Negative 
        
Tumor 5.1 Mixed; S + T Weak 
Tumor 5.2 Mixed; S + R Weak 
        
Tumor 6.1 Mixed; S + R Weak 
Tumor 6.2 Mixed; R + T Strong 
        
Tumor 7.1 Mixed; S + R + T Negative 
Tumor 7.2 Solid Weak 
        
Tumor 8.1 Solid Weak 
Tumor 8.2 Solid Weak 
        
Tumor 9.1 Solid Negative 
Tumor 9.2 Mixed; S + R Weak 
        
Tumor 10.1 Mixed; S + R Negative 
Tumor 10.2 Mixed; S + R Negative 
        
Tumor 11.1 Mixed; S + T Negative 
Tumor 11.2 Mixed; R + T Moderate 
        
Tumor 12.1 Solid Negative 
Tumor 12.2 Solid Negative 
        
Tumor 13.1 Mixed; S + T Strong 
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